Kaken Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3207000005
JPY
3,830.00
-15 (-0.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
19,254.00
18,261.00
20,489.00
18,867.00
18,045.00
24,618.00
33,118.00
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
19,254.00
18,261.00
20,489.00
18,867.00
18,045.00
24,618.00
33,118.00
Raw Material Cost
10,094.00
9,009.00
8,781.00
8,995.00
8,705.00
9,528.00
9,067.00
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
13.00
11.00
11.00
10.00
9.00
7.00
7.00
Selling and Distribution Expenses
5,674.00
4,927.00
5,229.00
4,476.00
5,557.00
4,665.00
4,247.00
Other Expenses
492.70
396.20
627.90
537.20
815.90
457.70
296.80
Total Expenditure (Excl Depreciation)
20,708.00
17,909.00
20,300.00
18,853.00
22,430.00
18,777.00
16,289.00
Operating Profit (PBDIT) excl Other Income
-1454
352
189
14
-4385
5841
16829
Other Income
2,539.00
219.00
815.00
408.00
-180.00
421.00
-18.00
Operating Profit (PBDIT)
2,103.00
1,408.00
1,838.00
1,058.00
-3,936.00
6,883.00
17,458.00
Interest
13.00
11.00
11.00
10.00
9.00
7.00
7.00
Exceptional Items
-745.00
28.00
-8.00
1.00
-2,010.00
531.00
59.00
Gross Profit (PBDT)
9,160.00
9,252.00
11,708.00
9,872.00
9,340.00
15,090.00
24,051.00
Depreciation
1,018.00
837.00
834.00
636.00
629.00
621.00
647.00
Profit Before Tax
329.00
587.00
988.00
409.00
-6,586.00
6,786.00
16,864.00
Tax
-418.00
182.00
267.00
137.00
-1,356.00
1,897.00
4,332.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
746.00
406.00
721.00
271.00
-5,230.00
4,889.00
12,532.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
746.00
406.00
721.00
271.00
-5,230.00
4,889.00
12,532.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
746.00
406.00
721.00
271.00
-5,230.00
4,889.00
12,532.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,47,619.00
1,45,808.00
1,47,802.00
1,47,447.00
1,52,635.00
1,55,259.00
1,54,405.00
Earnings per share (EPS)
19.7
10.72
19.04
7.12
-136.18
129.09
330.91
Diluted Earnings per share
19.7
10.72
19.04
7.12
-136.18
129.09
330.91
Operating Profit Margin (Excl OI)
-7.55%
1.93%
0.92%
0.07%
-24.3%
23.73%
50.82%
Gross Profit Margin
7.0%
7.8%
8.89%
5.54%
-33.01%
30.09%
52.87%
PAT Margin
3.87%
2.22%
3.52%
1.44%
-28.98%
19.86%
37.84%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is 6.70% vs 3.95% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 114.26% vs -487.41% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 88.39% vs -385.84% in Mar 2025

stock-summary

Interest

YoY Growth in quarter ended Mar 2026 is 44.44% vs 125.00% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Kaken Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(JPY)
Change(%)
Net Sales
19,254.00
9,966.00
9,288.00
93.20%
Other Operating Income
0.00
0.00
0.00
Total Operating income
19,254.00
9,966.00
9,288.00
93.20%
Raw Material Cost
10,094.00
3,429.00
6,665.00
194.37%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
13.00
90.00
-77.00
-85.56%
Selling and Distribution Expenses
5,674.00
3,082.00
2,592.00
84.10%
Other Expenses
492.70
329.90
162.80
49.35%
Total Expenditure (Excl Depreciation)
20,708.00
9,900.00
10,808.00
109.17%
Operating Profit (PBDIT) excl Other Income
-1,454.00
66.00
-1,520.00
-2,303.03%
Other Income
2,539.00
427.00
2,112.00
494.61%
Operating Profit (PBDIT)
2,103.00
1,032.00
1,071.00
103.78%
Interest
13.00
90.00
-77.00
-85.56%
Exceptional Items
-745.00
0.00
-745.00
Gross Profit (PBDT)
9,160.00
6,537.00
2,623.00
40.13%
Depreciation
1,018.00
539.00
479.00
88.87%
Profit Before Tax
329.00
402.00
-73.00
-18.16%
Tax
-418.00
27.00
-445.00
-1,648.15%
Provisions and contingencies
0
0
0.00
Profit After Tax
746.00
400.00
346.00
86.50%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
746.00
400.00
346.00
86.50%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
-24.00
24.00
100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
746.00
376.00
370.00
98.40%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,47,619.00
46,942.00
1,00,677.00
214.47%
Earnings per share (EPS)
19.70
3.27
16.43
502.45%
Diluted Earnings per share
19.70
3.27
16.43
502.45%
Operating Profit Margin (Excl OI)
-7.55%
0.66%
0.00
-8.21%
Gross Profit Margin
7.00%
9.44%
0.00
-2.44%
PAT Margin
3.87%
4.01%
0.00
-0.14%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 1,925.40 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 5.44% vs -10.87% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 6.70% vs 3.95% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 74.60 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 83.74% vs -43.69% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 114.26% vs -487.41% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -43.60 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -136.67% vs 16.23% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 88.39% vs -385.84% in Mar 2025

Quarterly - Interest
Interest 1.30 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 18.18% vs 0.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 44.44% vs 125.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -7.55%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025